Clinical analysis of allogeneic peripheral blood stem cell transplantation on treating myelodysplastic syndrome in 8 cases

ZHANG Jing-wen,ZHENG Yong-jiang,HU Yuan,CHEN Yu-xin,LIN Dong-jun

DOI: https://doi.org/10.3969/j.issn.1674-7445.2013.05.011

2013-01-01

Abstract:Objective To observe the therapeutic effect of allogeneic peripheral blood stem cell transplantation(allo-PBSCT) on myelodysplastic syndrome(MDS).Methods From May 2007 to January 2012,8 patients with MDS were treated with allo-PBSCT in Department of Hematology of the Third Affiliated Hospital of Sun Yat-sen University,including 2 males and 6 females with the age ranged from 18 to 50 years old(median age 31 years old).According to MDS classification standard(2008) from World Health Organization(WHO),patients were classified as refractory cytopenia with multilineage dysplasia(RCMD,n = 2),refractory anemia with excess blasts-1(RAEB-1,n = 1),RAEB-2(n = 3) and MDS progressed to acute myeloid leukemia(MDS-AML,n = 2).Hematopoietic stem cells were mobilized from the donor's peripheral blood after administering granulocyte-colony stimulating factor(G-CSF) at a dose of 5-10 μg /(kg·d) for 5 days,with apheresis for 1 or 2 days.Peripheral mononucleated cells were given to recipients with a dose of(5.8-11.6) ×108/ kg(median 7.7 × 108/ kg).The BuCy conditioning regimen was used in 6 cases,and the modified BuCy conditioning regimen was used in 2 cases,and antithymocyte globulin(ATG) was jointly used for unrelated PBSCT.Ciclosporin and methotrexate for short-course were used to prevent graft-versus-host disease(GVHD).Results The haematopoietic system were successfully reconstructed in 6 cases.The time of granulocyte recovery ≥ 0.5 × 109/ L and platelets ≥ 20 × 109/ L was 9-15 d(median 12 d) and 11-42 d(median 13 d) respectively.Four cases developed acute GVHD(aGVHD)(1 case of grade Ⅰ,2 cases of grade Ⅱ,1 case of grade Ⅳ).Six cases survived for more than 100 d and 3 of them developed chronic GVHD(cGVHD).Follow-up time was 2.6-56.9 mon(median 27.0 mon).Two cases died in 100 d after PBSCT,and the other 6 cases survived with disease-free.By Kaplan-Meier method,overall survival(OS) and disease-free survival(DFS) rates were both(75.0 ± 15.3) %,and estimated mean survival time was(43.4 ± 8.3) mon.Conclusions Allo-PBSCT is an effective treatment for young MDS patients.